Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    21498393 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
2 Withdrawn In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: AKTi-treated TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
3 Terminated
Has Results
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
4 Recruiting T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Conditions: Synovial Sarcoma;   Breast Cancer;   Non-Small Cell Lung Cancer;   Hepatocellular Cancer
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
5 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
6 Completed Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Drug: Aldesleukin
7 Recruiting Safety Study of Adoptive Transfer of Autologous IKDC-like Cells
Condition: Neoplasm Metastasis
Intervention: Other: autologous IKDC-like cells

Study has passed its completion date and status has not been verified in more than two years.